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Benjamin Turner1, Gavin Giovannoni1  
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London, 3Medical Statistics Department, London School of Hygiene and Tropical Medicine, London, 
United Kingdom, 4Department of Biomedicine, Aarhus University, Aarhus, Denmark, 5The Albion 
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Abstract 
Background: Although the aetiology of Multiple Sclerosis (MS) remains elusive, it is clear that Epstein 
Barr Virus (EBV) and possibly other viruses play a role in the pathogenesis of MS. Laboratory 
evidence suggests that Human Endogenous Retroviruses (HERVs) could also have a role, but no 
interventional therapy has determined what will happen if HERVs are suppressed. Recent 
epidemiological evidence indicates patients with HIV infection have a significantly lower risk of 
developing MS and that HIV antiretroviral therapies may be coincidentally inhibiting HERVs, or other 
retroelements, that could be implicated in MS. 
Objectives: To systematically investigate the effects of an HIV integrase strand inhibitor, raltegravir, 
on the number of gadolinium (Gd)-enhanced MRI lesions in people with active relapsing MS.  
Methods: This is a Phase 2a clinical trial where twenty participants were enrolled in a 3 month 
baseline phase followed by 3 months of treatment with raltegravir 400mg twice a day. Patients had 
monthly Gd-enhanced MRI, saliva collection to test for EBV shedding, blood sampling for safety 
monitoring, virology (including HERVs), measurement of immunological and inflammatory markers; 
and physical, neurological and quality-of-life assessments. 
Results: All patients completed the six months trial period.  
The primary outcome measure of MS disease activity was the number of Gd-enhancing lesions 
observed, and raltegravir had no significant effect on the rate of development of Gd-enhancing 
lesions during the treatment phase compared with the baseline phase. 
 Additionally, there was no change in secondary outcomes of either disability or quality-of-life 
measures that could reasonably be attributed to the intervention. There was a significant positive 
between HERV-W/MSRV (Multiple Sclerosis Related Virus) Gag Flix (Fluorescence index) B cells and 
the number of Gd-enhanced lesions at any visit (p = 0.029), which was independent of any potential 
influence of the trial drug administration. Regarding EBV shedding, there was no significant 
correlation between the amount of EBV shedding and the number of lesions.  No change was 
detected in inflammatory markers (IL-8, IL-1β, IL-6, IL-10, TNF, IL-12p70 and HCRP), which were all 
within normal limits both before and after the intervention. Serum CD163 expression was also 
unchanged by raltegravir. 
Conclusions: Raltegravir did not have any impact on MS disease activity. This could be due to the 
choice of antiretroviral agent used in this study, the need for a combination of agents, as used in 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
2 
 
treating HIV infection, the short treatment period or dosing regimen, or the lack of a role of HERV 
expression in MS once the disease is established. Borderline significance for the association between 
EBV shedding and the total number of lesions, probably driven by new lesion development, may 
indicate EBV shedding as a marker of inflammatory disease activity. In conclusion, interesting 
correlations between HERV-W markers, EBV shedding and new MRI lesions, independent from 
treatment effects, were found.  
Background 
2018 will be the 150th anniversary since Jean-Martin Charcot (1825-1893) published the triad of signs 
which denote multiple sclerosis (1); although Alastair Compston observes the actual timeline for 
describing MS cannot be so clearly attributed to Charcot (2). What is indisputable, however, is that 
in the past 150 or more years we have moved only marginally closer to finding the aetiology of MS. 
Moreover, there remains considerable debate about the pathogenesis of the disease; to the extent 
of no broad consensus on whether the different manifestations of MS are iterations of a single 
disease entity or, in fact different diseases, with the only consensus being that MS is a complex 
interaction between a genetic predisposition and environmental factors (3) resulting in an 
autoimmune dysregulation targeting  myelin. One of the more prevailing theories about the 
aetiology of MS is an as yet unconfirmed virus that triggers or causes the disease cascade (4). The 
most likely viral candidate is a herpes virus, possibly Epstein-Barr virus (EBV) which infects human 
primary B-cells and maintains a lifelong and persistent infection in memory B cells (5), depletion of 
memory B-cells seem to be increasingly associated with the pathogenesis of MS (6). However, the 
causal link between EBV and MS is unclear and until there is either an effective treatment or vaccine 
to control EBV, the nature of any association will remain unresolved. 
An inter-related theory about the aetiology of MS involves the role of human endogenous 
retroviruses (HERVs) which may be transactivated by EBV and triggered to express HERV encoded 
proteins. These proteins are considered as ‘foreign’ by the immune system and may trigger a B-cell 
response. The resulting antibodies may then cross-react with other proteins, inducing the 
autoimmune response that results in destruction of myelin. This process is called ‘molecular 
mimicry’ (7). Additionally, the HERV encoded proteins may act as superantigens (8, 9), and HERV 
encoded proteins may have neuropathogenic potential (10). Initial evidence for the possible 
involvement of HERVs in MS was suggested by Perron et al. in 1991 (11, 12) and by Christensen et al. 
(13, 14), but there has been no conclusive evidence. A recent meta-analysis on studies of the role of 
HERVs in MS concluded that adequate data were available to show there is an association between 
expression of HERVs, notably the HERV-W family and MS (15). The HERV-W family comprise a 
number of sequences of HERV-W/MSRV/Syncytin-1, originating from a mosaic of loci, essentially 
indistinguishable from a single locus by the methods hitherto used (16). The two HERV families 
HERV-W/MSRV and HERV-H/F are activated in MS, and levels of HERV antigens are increased on the 
peripheral blood mononuclear cells (PBMCs), particularly on B cells and monocytes (17, 18). 
This temporal cascade of laboratory evidence has been paralleled by clinical observations that 
describe MS-like presentations in patients who were diagnosed with the exogenous retrovirus 
Human Immunodeficiency Virus (HIV) infection (19). In these patients, it was presumed the MS 
symptoms were most likely manifestations of HIV-encephalopathy. In 2012, a case report of a man 
who was confirmed to have both HIV and RRMS and appeared to go into long term remission from 
his RRMS  when he was treated with HIV antiretroviral (ARV) therapy (20). The hypothesis  is that 
ARVs may inhibit HERVs as well as inhibiting HIV and thus ARVs may ameliorate RRMS. In order to 
explore this observation further a Phase 2 baseline versus treatment clinical trial was planned to 
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investigate the role of the Integrase inhibitor, raltegravir, in patients with active RRMS, as defined by 
the presence of a gadolinium enhanced lesion on MRI scanning at baseline. 
Raltegravir (Isentress®, Merck and Co., Inc., Whitehouse Station, NJ, USA) is a twice daily oral 
integrase strand transfer inhibitor approved for treating HIV infection in 2007, in combination with 
other antiretroviral agents. Its safety profile has been confirmed during more than 10 years of use 
(21). Raltegravir was chosen as it has a proven safety profile and, as there are not available in-vitro 
data on the effectiveness of antiretroviral therapy in HERVs, we decided that a single agent would be 
appropriate for an initial investigation as was also the case in the initial clinical studies of HIV. 
Participants and Methods 
Primary efficacy outcome: To determine a reduction in the number of new or recurrent Gd-
enhancing lesions that appear on brain T1-weighted MRI over the period of treatment with 
raltegravir, compared to  baseline. 
Secondary efficacy outcomes: Determine the cumulative number of new or enlarging T2 weighted 
lesions on brain MRI. Determine specific inflammatory markers of MS activity. Determine specific 
indicators of endogenous retroviral activity and activity of herpes viruses.  Determine Multiple 
Sclerosis Functional Composite (MSFC), Kurtzke Extended Disability Status Scale (EDSS), Multiple 
Sclerosis Quality of Life Inventory (MSQLI).Participants 
Adult patients 18-55 years of age with active RRMS according to the revised McDonald Criteria 
(2010), determined as having at least one documented relapse within the last 12 months or at least 
one Gd-enhancing lesion on brain MRI during the 3 months prior to screening and an EDSS score not 
exceeding 6.0, were eligible to enrol in the study. Additionally, participants had to meet standard 
inclusion and exclusion criteria. After enrolment in the study, participants had a baseline Gd-
enhanced MRI and if there was an active lesion they entered a 3 months observation period, during 
which they received no raltegravir, followed by 3 months on treatment. All participants were 
recruited at the Clinical Research Centre of the Royal London Hospital and were drawn from the 
catchment area of greater London. A total of 31 participants were screened, of these 8 had no 
evidence of Gd enhancing lesions in their baseline MRI and were screen failed.  Of the 23 
participants who were recruited into the study 3 were withdrawn prior to starting the treatment 
phase; one at the request of the participant and the remaining two due to MS relapse. Medications 
for spasticity, bladder control, fatigue and other MS symptoms were permitted. Administration of 
oral or IV steroids for clinical exacerbation of MS was also permitted as follows: for oral 
administration: up to 500 mg of methylprednisolone daily for no more than 5 days; for IV 
administration: up to 1 g of methylprednisolone daily for no more than 3 days. 
This study was given ethical approval by NRES Committee East of England – Cambridge East. Further 
amendments were made which also gained ethical approval from the same Ethics Committee. 
Clinical Assessment 
 
 
 
 
 
before treatment on treatment 
1  
screening 
2 3 4 5 6 7 8 
MRI MRI MRI MRI MRI MRI MRI 
blood blood blood blood blood blood blood 
EDSS EDSS EDSS EDSS EDSS 
blood 
MSFC MSFC MSFC MSFC MSFC MSFC MSFC 
QOL QOL QOL QOL QOL QOL QOL 
treatment dispensed 
visits: 
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During the pretreatment observation period (day 0 to day 84 ) participants attended 3 visits at 
baseline, day 28 and day 56. Treatment was first dispensed at the fourth visit, on day 84, after which 
patients were treated with open label raltegravir 400mg twice daily; participants then attended 
three visits during the treatment period, at day 112, 140 and 168 (end of study).Gd enhanced brain 
MRIs were performed every 4 weeks from baseline through study day 168 (end of study visit). Only 
MRIs of the brain were performed. MRI performed during the pretreatment observation period 
provided data on the baseline number of lesions and the rate of development of lesions. MRI 
performed during on-treatment period provided data for comparison with pretreatment period. MRI 
examinations of the brain were standardized to ensure sufficient image quality for the evaluation of 
radiographic progression of multiple sclerosis. This assessment was performed in the NMR Unit of 
The Institute of Neurology, UCL, Queen Square. Outcome assessments for biomarkers were collected 
at visits 1-8 and transferred to the Blizard Institute laboratory for analysis. The Institute for 
Biomedicine at the Aarhus University in Denmark were also contracted to analyse virology samples 
for HERVs according previously published methodology (22). In summary, The expression of HERV  
encoded proteins was assessed by flow cytometric analysis on isolated PBMCs using a Novocyte 
Acea Bioscences Flow cytometer. Polyclonal antibodies against HERV peptide antigens were raised in 
New Zealand White rabbits. The peptide epitopes are localized at equivalent positions in ORFs at the 
respective HERV loci. Both peptides and antisera were by Sigma Genosys (UK). Antibody binding to 
targets was visualised using goat anti-rabbit Alexa 488. The peptide antigens were: HERV-W/MSRV 
Env W1 and W3 (aa415–431, and aa301–317, respectively, AF208161.1), HERV-W/MSRV Gag (aa 
231-246, AF123881.1); HERV-H/F Env H1 and H3 (aa489–505, and aa 370–386, respectively, 
AJ289709), and HERV-H/F Gag (aa380-395, AL354685). Preimmune sera were collected from all 
rabbits before immunization, and fluorescence indexes (Flix) determined as fluorescence intensity of 
immune vs preimmune serum.  Staining for B cells and monocytes, respectively, was performed 
using mouse anti-human anti-CD3 eFluor 450, mouse anti-human anti-CD14 PE, and mouse anti-
human anti-CD20 APC. 
Data collected included gender, age, age of onset, ethnicity. Assessments conducted during the visits 
included neurological examination and EDSS. Blood and saliva samples were collected for 
biochemical, virological and viral immunological analysis including exposure to other viruses (HSV, 
VZV, EBV, CMV, and HHV-6) and inflammatory markers. The following quality of life parameters 
were measured at each trial visit: Patient Questionnaire  using the  SF36 - Physical Functional Score; 
Role-Physical Scale ; Bodily Pain Scale; General Health Scale ; Vitality Scale ; Social Functioning Scale ; 
Role Emotional Scale ; Mental Health Scale. Patient Questionnaire using the Modified Fatigue 
Assessment Scale and the MOS Pain Effects Scale Assessment. 
Statistical methods 
 
The primary efficacy analysis was a comparison between the rate of Gd enhancing T1-weighted 
lesions appearing on the monthly brain MRI over the treatment period, compared to the pre-
treatment observation period.  The sample size was based on Sormani et al(23), indicating that for a 
before-after design with number of Gd-enhancing lesions counted at baseline, 19 patients are 
required to detect, with 80% power at 5% significance, a 40% reduction in the number of Gd-
enhanced lesions.  We planned to enrol 24 to allows for patient dropout. The analysis was 
performed using the counts of new or persisting lesions as the outcome variable in a mixed effects 
Poisson regression, with a linear predictor containing a binary indicator for the counts occurring on 
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treatment vs pre-treatment, and as covariate the baseline (visit 2) count for each patient (log 
transformed for consistency with the Poisson model).  This type of model, which allows for within-
patient lack of independence, estimates the count rates before and on treatment, and the 
corresponding rate ratio with a Wald test of this ratio.  A second mixed effects Poisson regression 
with the same outcome used a linear predictor containing the month of follow-up and an interaction 
between month and the binary indicator above, with the baseline visit count as covariate.   This 
model estimates the change in monthly rates over time, in other words, the count ‘gradient’ during 
each period, and tests (Wald) for a change in gradient: it is important to estimate these gradients 
because if there were a decline already during the pre-treatment period, a lower overall treatment 
lesion rate could not plausibly be attributed to the treatment, since it could reflect a decline over 
time independent of, and starting before, treatment.    T2-weighted lesions counts, which were only 
observed twice, at visits 5 (before) and 8 (after treatment), were compared with a Wilcoxon signed-
ranks test of the within-person changes.  Linear mixed models were used similarly to compare mean 
values of continuous outcomes before and during treatment (with similar linear predictors to 
Poisson models, and again with additional models estimating gradients before vs during treatment), 
of a) specific inflammatory markers of MS; b) specific indicators of endogenous retroviral and herpes 
virus activity; c) clinical and quality of life measures.  Linear mixed models with HERV outcomes and 
time-varying lesion counts as predictors were used to investigate potential associations between 
these two measures at any given time-point. 
Results 
 
A total of 31 participants were screened; of these 8 had no evidence of Gd enhancing lesions in their 
baseline MRI and were not eligible to enter the baseline phase.  Of the 23 participants who were 
recruited into the study 3 were withdrawn prior to starting the treatment phase; one at the request 
of the participant and the remaining two due to MS relapse. 20 participants entered the treatment 
phase and completed the 12 week treatment period. They received the recommended dose of open 
label Isentress-Raltegravir (MA number: EU/1/07/436/001) 400mg twice a day administered as a 
potassium salt in a film coated tablet.  
 
The intention-to-treat (ITT) population includes all participants recruited who received at least one 
dose of study medication. Data for all 20 participants enrolled in the study was used in the ITT 
analysis.  There were four participants who were regarded as being protocol deviations; two due to 
an error in the original protocol and two due to intermittent use of inhaled steroids for a respiratory 
illness that was temporary. The Investigators determined the reasons for these deviations did not 
influence the potential outcomes of the trial and as all participants finished the 24 weeks of baseline 
and treatment, data are presented as an ITT analysis. Participant characteristics are given in Table 1, 
showing a majority of females, minimal disability, but quite active RRMS in terms of relapses. 
 
Table 1: Baseline Characteristics 
 
Characteristic  
Age, years: mean (SD) 41 (7.0) 
Female: n (%) 14 (70%) 
Number of relapses in 
past year: mean (SD) 
 
1.50 (0.61) 
Baseline EDSS:  
mean, median (SD) 
 
2.40, 2.50 (1.03) 
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 There were no clinically significant biochemical safety issues requiring either participant withdrawal 
or variation of the prescribed dose and/or frequency of raltegravir administration. The mean 
number of visits with any adverse events were very similar during the baseline phase (2.35) as during 
the treatment phase (2.30); there were a total of 245 adverse events in the 31 screened patients 
with one SAE due to a  hospitalisation, for social reasons, which was considered not to be associated 
with raltegravir. 
 
 Treatment Effect 
Gd Enhanced MRI outcomes 
 
T1 lesions (i.e. Gd-enhancing) 
 
No statistically significant differences were found in the after vs before medication periods for either 
T1 or T2 weighted lesion counts, or for the T1 lesions broken down by new or persisting lesions. The 
mean number of T1 lesions per visit was 3.08 (range 0-16) and the median number was 2. Visit 2 was 
the enrolment visit when all participants needed to have at least one Gd-enhanced lesion in order to 
enter the baseline phase. This visit is excluded from the comparative before versus after analysis. 
   
 
Table 2 compares the counts and rates for new and persisting T1 Gd-enhanced lesions, showing a 
very slight and non-significant increase in rate for the on-treatment vs pre-treatment period (rate 
ratio 1.04, p=0.681). 
Table 2: Counts and rates for new plus persisting T1 Gd-enhanced lesions 
  Before treatment 
(visits 3, 4, 5) 
On treatment 
(visits 6, 7, 8)  
  
  Total 
count 
Monthly 
rate 
Total 
count 
Monthly 
rate 
Rate 
ratio
a
 
95% Confidence 
interval; p-value 
Mean 8.65 2.89 9.05 3.02 1.04 0.85, 1.29; p=0.681 
Median 6.00 2.00 6.00 2.00   
Min 0 0.00 0 0.00   
Max 32 10.67 31 10.33   
a
Estimated within-patient rate ratio, confidence interval and p-value obtained from mixed-
effect Poisson model adjusting for baseline (visit 2) counts.  
 
The difference in the rates of change (‘gradients’) of the monthly counts before vs on treatment was 
also non-significant, P=0.659. 
Separate comparisons of new and persisting T1 Gd-enhanced lesions gave rate ratios, on vs pre-
treatment, which showed a small non-significant increase for new (rate ratio 1.16, p=0.314) and a 
small non-significant decrease (rate ratio 0.93, p=0.652) for persisting lesions. 
 
T2 Weighted lesions 
   
Table 3 compares total counts of new or enlarging T2-weighted lesions at visit 5 (before) and visit 8 
(after treatment) and shows a very slight and non-significant increase in these lesions. 
Table 3. T2-weighted new or enlarging lesions before and after treatment 
  
Before treatment 
(visit 5) count 
After treatment 
(visit 8) count Count ratio p-value
a
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Mean 4.45 4.65 1.05 0.472 
Median 3.00 3.00   - 
Min 0 0   - 
Max 17 20   - 
  
a 
Wilcoxon signed-ranks test of within-person changes 
   
Virologic Results 
Human endogenous retrovirus(HERV) 
Quantitative measurement of HERVs were conducted in the Department of Biomedicine, University 
of Aarhus, Denmark by Tove Christensen. The HERVs were HERV-W/MSRV); and HERV H/F. There 
was no significant association between the quantitation of either HERV and baseline or treatment 
phases.  
While there was no evidence of association with treatment, there was an independent significant 
association between the number of new T1 Gd-enhancing lesions and an increase in expression of 
HERV-W Gag on B cells; while overall HERV-W/MSRV Gag Flix B cells values varied during both trial 
periods, throughout the trial higher T1 Gd-enhanced lesion counts at any individual visit were 
associated with higher values of HERV-W/MSRV Gag Flix B cells values at that visit: entering the 
monthly Gd lesion counts into the linear mixed model for ITT suggests that during the trial period, 
having one additional lesion at a visit predicts a HERV-W/MSRV Gag Flix B cells increase of 0.008 
(dimensionless, 95% CI .00082,  .01521), P= 0.029.  This was also reflected in a borderline significant 
association whereby patients with larger decreases in mean HERV-W/MSRV Gag Flix B cells values 
during the two trial periods tended to have larger decreases in corresponding mean T1 Gd-enhanced 
mean lesion count: Spearman r=0.46, P=0.057.    
 
 
 
Epstein - Barr virus (EBV) 
There were no associations between quantitative PCR measurements of EBV in saliva specimens and 
number of T1 lesions.  When EBV was dichotomized (0 / >0), there was a lower odds of having EBV>0 
with a greater number of total lesions (odds ratio 0.79 per lesion, P=0.081); this was more probably 
driven by new lesions (P=0.097) than persisting lesions (P=0.442). However, the number of 
analyzable saliva samples was relatively small. It was observed that about 40% of participants shed 
EBV at some time during the six months of saliva collection and that the cross-sectional prevalence 
of EBV shedding was about 15%. 
 
Inflammatory Markers 
No change was detected in inflammatory markers (IL-8, IL-1β, IL-6, IL-10, TNF, IL-12p70 and HCRP), 
which were all within normal limits during the baseline phase and during the treatment phase. 
Serum CD163 expression was also unchanged by Raltegravir. 
Disability Measurements 
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There was no statistically significant change in either the means or gradients for EDSS and the 
25FTW. There was a significant improvement in both the PASAT and the 9HPTmean scores during 
the course of the trial, but the improvement gradient was similar in both trial periods, suggesting 
either a learning effect or a trial participation effect. 
Quality-of-life Measurements 
Table 5: Quality of Life Scores SF36; MOS Fatigue Assessment and PES 
Measure n Change in means P-value
c
 
        
PQ - SF36 - Physical Functional Score
a
 20 -0.92 0.685 
PQ - SF36 - Role-Physical Scale
a
 20 -9.48 0.034 
PQ - SF36 - Bodily Pain Scale
a
 20 -5.42 0.024 
PQ - SF36 - General Health Scale
a
 20 -4.67 0.001 
PQ - SF36 - Vitality Scale
a
 20 5.06 0.011 
PQ - SF36 - Social Functioning Scale
a
 20 2.45 0.414 
PQ - SF36 - Role Emotional Scale
a
 20 -8.62 0.096 
PQ - SF36 - Mental Health Scale
a
 20 5.72 0.013 
PQ - PFA - Patient Fatigue Assessment
b
 20 -1.51 0.683 
PQ - PPA - Patient Pain Assessment
b
 19 4.07 0.144 
PQ - MSIS - Total Score
b
 20 -2.10 0.220 
PQ - MSWS-12 - MSWS Total Score
b
 20 -0.35 0.772 
a
Improvement is represented by positive change. 
b
Improvement is represented by negative change. 
c
Obtained from linear mixed models using all time points. 
There appeared to be significant changes in some of the Quality of Life parameters during the course 
of the trial, but these changes are not plausibly attributable to treatment, as mentioned later.  
Discussion 
This Phase 2 baseline versus treatment open label clinical trial was designed to determine the 
efficacy of the integrase strand transfer inhibitor, raltegravir, in patients with active relapsing 
remitting multiple sclerosis. The aim of the trial was to investigate if raltegravir may inhibit a HERV 
and thereby ameliorate the possible role of HERV in active RRMS as measured by Gd-enhanced 
lesion development. Raltegravir did not provide statistically significant evidence of efficacy in the 
primary outcome measure, reduction in the number and rate of development of T1 lesions by Gd-
enhanced MRI during the treatment phase compared with the baseline phase. An alternative 
outcome measure to enhancing lesions seen on monthly Gd-enhanced MRI is the number of new or 
enlarging T2 lesions seen on T2-weighted scans over longer intervals. In our study, this outcome 
measure was analysed for the 3-month baseline and treatment periods and showed no evidence for 
treatment efficacy (Table 3). There was also no improvement in the secondary outcomes of 
quantitative virological measurements or inflammatory markers.  Improvements in disability or 
quality-of-life measures are most probably attributable to a placebo effect of treatment or of 
general trial participation. Raltegravir did not produce any significant increase in adverse events 
during the treatment phase compared with the non-treatment baseline phase. Two experimental 
findings, unrelated to treatment, were interesting and previously unreported: that HERV-W tended 
to increase in association with increasing number of new T1 lesions and quantitative EBV shedding in 
saliva also paralleled increase in observed new T1 lesions.  However, these associations must be 
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interpreted with caution and regarded only as hypothesis generating for future confirmation, since 
they are vulnerable to type I statistical error. 
There are a number of possible reasons why raltegravir appears to have had no observed efficacy in 
this clinical trial. The clinical trial design, which was taken from the model proposed by Somani et al 
(23). was considered the most feasible in the circumstances of not having extensive evidence of 
effect in animal models. The trial was of limited duration with the baseline and treatment phases 
each of 12 weeks which was determined by the investigators as a clinically reasonable period for 
which patients with active disease could remain not taking a disease modifying therapy.  The single 
agent, raltegravir, was not in a combination of antiretroviral therapies as has been shown to be 
effective in treating the exogenous retrovirus, HIV. While there is no direct link between HIV therapy 
and the possibility that MS is triggered or caused by a HERV, we believe it would have been 
preferable to administer a combination of antiretroviral agents that act on different phases in the 
possible life-cycle of an endogenous retrovirus. This idea may be supported by the NHS record 
linkage study that found a significantly reduced incidence of MS in patients who had HIV infection 
compared with a large control population. The possibility that these patients were also taking 
combination ARVs supports the hypothesis that ARVs may influence the activity of a HERV which 
could trigger or cause MS (24). 
Given that patients received just 12 weeks of raltegravir administration, the ARV would need to have 
had an impact almost immediately in order to cause a biological (anti-inflammatory) effect on the 
development of new Gd-enhancing lesions. We know this is not the case with HIV infection where it 
may take some weeks for an ARV combination to fully suppress HIV. While there are no in-vivo data 
on HERVs, it is possible that it may require weeks or months of treatment to achieve a therapeutic 
effect on an endogenous retrovirus. The dose and frequency of raltegravir was chosen as this is the 
licensed regimen for treatment of HIV infection. However, there are no data on the use of raltegravir 
in RRMS and treating possible HERV production. It is possible the dose level and frequency may need 
to be much higher than for HIV; it is possible that the dose and frequency of administration should 
be different in RRMS. This observation has been recently supported by laboratory data for HERV-K, 
which although not a purported cause of MS, provides some indication as to the required 
concentration of raltegravir to inhibit a HERV. The linkage between HERVs and MS is being explored 
in a Phase 2b clinical trial that is investigating the use of GNbAC1 at three dose levels compared with 
placebo in 270 patients who have RRMS (25). This trial has fully enrolled and the results should 
provide information on the role of a humanized monoclonal antibody against the envelope protein 
of HERV-K (MSRV). This trial should further advance the field of investigating the possible role of 
HERVs and MS. 
In conclusion, the INSPIRE trial was the first clinical study on using an HIV antiretroviral therapy to 
treat RRMS. While the results did not demonstrate a statistically significant improvement in either 
the primary or secondary outcomes, it did provide another step in the search for an aetiology of 
multiple sclerosis. 
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